Our finding of lipid pathway dysregulation in COVID-19 isaligned with a recent randomized controlled trial of proprotein convertasesubtilisin/kexin type 9 (PCSK9) inhibition using the monoclonal antibodyEvolucumab.61 Evolocumab treatment decreasedinflammation and mortality of patients with acute COVID-19.61 PCSK9 is a critical regulator of lipid levelsbecause PCSK9 regulates low-density lipoprotein receptor recycling,thereby modulating LDL62 levels. Here, VLDLR is linked to COVID-19.